Stock Events

Stock Events

Hemogenyx Pharmaceuticals 

€5.15
36
-€0.65-11.21% 15:47 Today

Statistics

Day High
5.6
Day Low
5.15
52W High
19.2
52W Low
4.48
Volume
-
Avg. Volume
-
Mkt Cap
31.11M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.28MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5HU0.STU. It's not an investment recommendation.
Tesla
4
TSLA
National Grid
4
NG.LSE
Legal & General Group
3
LGEN.LSE
Apple
2
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is involved in gene editing, a technology Hemogenyx could utilize in developing its therapies for blood-related diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap35.61B
Alnylam Pharmaceuticals is pioneering RNAi therapeutics, a novel form of treatment that could overlap with Hemogenyx's target diseases.
Novartis
NVS
Mkt Cap304.1B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for blood disorders, directly competing with Hemogenyx's focus area.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong presence in the treatment of blood diseases, including cell therapies, which puts it in competition with Hemogenyx.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.88B
BioMarin Pharmaceutical focuses on rare genetic diseases, some of which involve blood disorders that could be targeted by Hemogenyx's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.42B
Vertex Pharmaceuticals engages in creating new therapies for genetic diseases, including blood disorders, competing with Hemogenyx's research focus.
AMGEN
AMGN
Mkt Cap236.38B
Amgen has a diverse portfolio in biotechnology, including treatments for blood disorders, making it a competitor to Hemogenyx.
Pfizer
PFE
Mkt Cap162.16B
Pfizer, with its extensive research and development in various therapeutic areas, including blood disorders, competes with Hemogenyx's niche focus.

About

Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.
Show more...
CEO
Vladislav Sandler
Employees
16
Country
United Kingdom
ISIN
GB00BQVXM815
WKN
000A40WGA

Listings

STU
DE
5HU0.STU
STU
DE
5HU.STU
F
DE
5HU0.F
LSE
GB
HEMO.LSE

0 Comments

Share your thoughts

FAQ

What is Hemogenyx Pharmaceuticals stock price today?▼
The current price of 5HU0.STU is €5.15 EUR — it has decreased by -11.21% in the past 24 hours. Watch Hemogenyx Pharmaceuticals stock price performance more closely on the chart.
What is Hemogenyx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Hemogenyx Pharmaceuticals stocks are traded under the ticker 5HU0.STU.
Is Hemogenyx Pharmaceuticals stock price growing?▼
5HU0.STU stock has fallen by -18.25% compared to the previous week, the month change is a -27.97% fall, over the last year Hemogenyx Pharmaceuticals has showed a -36.42% decrease.
What is Hemogenyx Pharmaceuticals market cap?▼
Today Hemogenyx Pharmaceuticals has the market capitalization of 31.11M
What is Hemogenyx Pharmaceuticals revenue for the last year?▼
Hemogenyx Pharmaceuticals revenue for the last year amounts to 0 EUR.
What is Hemogenyx Pharmaceuticals net income for the last year?▼
5HU0.STU net income for the last year is -11.28M EUR.
How many employees does Hemogenyx Pharmaceuticals have?▼
As of September 08, 2026, the company has 16 employees.
In which sector is Hemogenyx Pharmaceuticals located?▼
Hemogenyx Pharmaceuticals operates in the Health & Wellness sector.
When did Hemogenyx Pharmaceuticals complete a stock split?▼
The last stock split for Hemogenyx Pharmaceuticals was on December 13, 2024 with a ratio of 1:400.
Where is Hemogenyx Pharmaceuticals headquartered?▼
Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.